Consistently, the GSE91061 dataset from GEO database also indicated that melanoma patients with higher PD-L2 expression had better clinical response to an anti-PD-1 antibody nivolumab immunotherapy (Fig. 2e). Here, PDCD1LG2 is linked to melanoma.